Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

Completed · Not applicable

Conditions studied: Adult Solid Neoplasm, Toxicity, Lymphoma

In brief

This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body. A geriatric assessment may identify risk factors for cancer treatment toxicity and may improve outcomes for older patients with advanced cancer.

Key facts

Study ID

NCT02054741

Run by

Supriya Mohile

People needed

733

Starts

2014-07-29

Expected to finish

2021-10-31

Last updated by the study team

2024-04-12

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• INCLUSION CRITERIA FOR PHYSICIANS
• Oncology physicians must work at a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) practice site with no plans to leave that NCORP practice site or retire at the time of enrollment into the study
• INCLUSION CRITERIA FOR PATIENTS
• Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed
• Plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration; the treatment regimen is up to the discretion of the treating oncology physician; the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity; patients who will receive monoclonal antibody therapy or other cancer therapies (e.g., tyrosine kinase inhibitors) are eligible if other agents present a prevalence of toxicity similar to chemotherapy; patients who are receiving approved cancer treatment in combination with radiation are eligible; a patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met. *Chemotherapy is defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) that have a prevalence of grade 3-5 toxicity in older patients similar to chemotherapy (>50%) will be allowed.
• Plan to be on chemotherapy or other allowable treatment for at least 3 months (minimum 70 days) and be willing to come in for study visits
• Have at least one geriatric assessment domain meet the cut-off score for impairment other than polypharmacy
• Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit. If the participant is found to be impaired on the Blessed-Orientation Memory Concentration Test (BOMC) during screening; they must have a health care proxy or authorized representative to be eligible to enroll.
• Participant has adequate understanding of the English language

You may not qualify if…

• EXCLUSION CRITERIA FOR PATIENTS
• Have surgery planned within 3 months of consent; patients who have previously received surgery are eligible
• Presence of symptomatic brain metastases at time of study consent process. Patients with a history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment.

Where it is running

• City of Hope — Duarte, California, United States
• Delaware/Christiana Care NCORP — Newark, Delaware, United States
• Hawaii MU-NCORP — Honolulu, Hawaii, United States
• University of Chicago — Chicago, Illinois, United States
• Heartland NCORP — Decatur, Illinois, United States
• Kansas City NCORP — Prairie Village, Kansas, United States
• Wichita NCORP — Wichita, Kansas, United States
• Gulf South MU-NCORP — New Orleans, Louisiana, United States
• Cancer Research Consortium of West Michigan — Grand Rapids, Michigan, United States
• Metro Minnesota NCORP — Minneapolis, Minnesota, United States
• Kansas City NCORP — Kansas City, Missouri, United States
• Nevada NCORP — Las Vegas, Nevada, United States
• North Shore LIJ Health System NCORP — Lake Success, New York, United States
• University of Rochester — Rochester, New York, United States
• Southeast Clinical Oncology Research Program — Winston-Salem, North Carolina, United States
• Columbus NCORP — Columbus, Ohio, United States
• Dayton NCORP — Dayton, Ohio, United States
• Pacific Cancer Research Consortium Ncorp — Portland, Oregon, United States
• Geisinger Cancer Institute NCORP — Danville, Pennsylvania, United States
• NCORP of the Carolinas — Greenville, South Carolina, United States
• Northwest NCORP — Tacoma, Washington, United States
• Wisconsin NCORP — Marshfield, Wisconsin, United States
• Aurora NCORP — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.